Coegi used more than 500 million impressions and paid social optimized with attention and emotion metrics to drive 24% of ...

The Cambridge-based company’s latest COVID shot was approved three weeks earlier than last year, according to a statement ...

Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...

Moderna posted a surprising third-quarter profit, driven by cost-cutting and higher-than-expected Covid vaccine sales.

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...

Bank of America Securities analyst Alec Stranahan reiterated a Hold rating on Moderna (MRNA – Research Report) today and set a price ...

Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...

Also Read: DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions In October, the FDA issued the ...

Moderna’s (NASDAQ:MRNA ... citing unfavorable CDC recommendations and timing of COVID vaccinations as reasons for the decline. Despite disappointing sales, all three vaccine makers cite better ...

Novavax has received the green light from the US Food and Drug Administration (FDA) to resume clinical trials for its ...

The number of COVID cases increased last week to 146. Cases had been falling in April and May and were as low as 31 at the ...